Nanobiotix

Company Profile

Nanobiotix had its IPO on 2020-12-11 under the ticker symbol NBTX.

The company operates in the Healthcare sector and Biotechnology industry. Nanobiotix has a staff strength of 102 employees.

Stock update

Shares of Nanobiotix opened at $9.48 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $9.38 - $9.64, and closed at $9.51.

This is a -4.76% slip from the previous day's closing price.

A total volume of 67,201 shares were traded at the close of the day’s session.

In the last one week, shares of Nanobiotix have increased by +1.15%.

Nanobiotix's Key Ratios

Nanobiotix has a market cap of $328.67 million, indicating a price to book ratio of 73.0056 and a price to sales ratio of 54.2746.

In the last 12-months Nanobiotix’s revenue was $4.78 million with a gross profit of $4.78 million and an EBITDA of $-45151000. The EBITDA ratio measures Nanobiotix's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Nanobiotix’s operating margin was -957.22% while its return on assets stood at -35.38% with a return of equity of -198.69%.

In Q2, Nanobiotix’s quarterly earnings growth was a positive 0% while revenue growth was a positive 159.6%.

Nanobiotix’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.82 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nanobiotix’s profitability.

Nanobiotix stock is trading at a EV to sales ratio of 8474.9785 and a EV to EBITDA ratio of -2.8381. Its price to sales ratio in the trailing 12-months stood at 54.2746.

Nanobiotix stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$59.77 million

Total Liabilities

$37.94 million

Operating Cash Flow

$26500.00

Capital Expenditure

$39500

Dividend Payout Ratio

0%

Nanobiotix ended 2024 with $59.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $59.77 million while shareholder equity stood at $-27045000.00.

Nanobiotix ended 2024 with $0 in deferred long-term liabilities, $37.94 million in other current liabilities, 1046000.00 in common stock, $-57041000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $41.39 million and cash and short-term investments were $41.39 million. The company’s total short-term debt was $4,560,000 while long-term debt stood at $0.

Nanobiotix’s total current assets stands at $52.36 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $7.99 million compared to accounts payable of $4.00 million and inventory worth $2.98 million.

In 2024, Nanobiotix's operating cash flow was $26500.00 while its capital expenditure stood at $39500.

Comparatively, Nanobiotix paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$9.51

52-Week High

$11

52-Week Low

$1.75

Analyst Target Price

$8.8

Nanobiotix stock is currently trading at $9.51 per share. It touched a 52-week high of $11 and a 52-week low of $11. Analysts tracking the stock have a 12-month average target price of $8.8.

Its 50-day moving average was $8.19 and 200-day moving average was $5.11 The short ratio stood at 0.22 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 993.3% are held by institutions.